**Title: Precision Medicine: Expanding the Scope of Pathology**

**Authors:** 1. Dr Sanjeet Kumar Singh, Additional Professor, Pathology and Lab Medicine, AIIMS, Deoghar

2. Dr Asitava Deb Roy, Additional Professor, Pathology and Lab Medicine, AIIMS, Deoghar

3. Dr Prima S Lakra, Assistant Professor, Pathology and Lab Medicine, AIIMS, Deoghar

4. Dr. Anita Kumari, Associate Professor, Physiology, AIIMS, Deoghar

Introduction:

Precision medicine, an innovative approach to medical treatment, aims to tailor healthcare decisions and medical interventions to individual patients by considering their genetic makeup, lifestyle, and environmental factors. In its initial conception, personalized medicine denoted the customization of medical care based on the unique traits of each patient, ultimately prompting a transformation in the clinical treatment approach from trial and error to ensuring the precise drug for the specific patient at the optimal moment, "the right drug, for the right patient, at the right time."

While this paradigm shift has led to remarkable advancements in various medical fields, including oncology, its successful implementation relies heavily on accurate and comprehensive pathology. Pathology, traditionally concerned with the study of disease and its effects on the body's tissues, has been a cornerstone of medical diagnostics and treatment planning. However, in the era of precision medicine, the role of pathology must evolve to encompass a wider range of factors, including molecular analysis, advanced imaging techniques, and integration with cutting-edge technologies.

The Evolving Landscape of Precision Medicine

The core principle of precision medicine revolves around treating patients as unique individuals, rather than applying one-size-fits-all treatments. This involves understanding the molecular and genetic basis of diseases to identify specific drivers and vulnerabilities that can be targeted with personalized therapies.1 In oncology, for instance, molecular profiling of tumors has led to evolution of targeted therapies that attack the underlying genetic alterations responsible for cancer growth.

Widening the Aperture: Beyond One Size Fits All

The driving force behind this transformation is rooted in the progress made in diagnostics, digital devices, and imaging technologies, complemented by a suite of analytical tools operating across various institutions and involving multiple stakeholders. In the past, precision medicine (PM) was associated with data derived from the design of therapy selection based on targeted genomic panels.

In the present day, amid the collection of data gathering on a population-wide scale and the accumulation of numerous data points, it's is right to describe the data as the fuel of our era. In addition to producing immense volumes of data, healthcare systems are increasingly proficient at seamlessly integrating and aggregating these datasets, thereby improving accessibility. This aggregation and integration of data are enabling us to complete the circle in comprehending patients, starting from their symptoms, progressing through treatment, and ultimately arriving at outcomes.2

Harnessing Real-Time Physiology: The Power of Predictive Algorithms

The emergence of innovative technologies and mobile medical applications has enabled us to actively monitor a patient's physiological status in real-time. In contrast to our earlier practice of gathering descriptive statistics for distinct population groups, we can now harness multidimensional data to develop predictive algorithms. These algorithms utilize collective learning to forecast outcomes for individual cases. In order to further advance the possibilities of precision medicine, those involved in healthcare are actively working to enhance their abilities across three key areas: collecting relevant data, analyzing that data, and making decisions based on analytical insights.3 One recent example is Tempus4, which describes itself as a most extensive repository of clinical notes, pathology images, and molecular data worldwide, along with an operational system designed to render this data accessible and beneficial, with an initial focus on cancer."

The Role of Pathology in Precision Medicine

Pathology traditionally involves the examination of tissues and cells to diagnose diseases, guide treatment decisions, and predict patient outcomes. In the context of precision medicine, pathology extends beyond conventional practices by integrating molecular profiling, genomics, proteomics, and other "omics" data to provide a more comprehensive understanding of each patient's disease. By analyzing the genetic makeup and molecular characteristics of tumors or diseases, pathologists can identify specific genetic mutations or markers that can guide targeted therapies and personalized treatment plans.5

The Genomic Revolution and Pathology

The advent of next-generation sequencing (NGS) technologies has revolutionized our understanding of the molecular basis of diseases. Genomic alterations, including mutations, copy number variations, and epigenetic modifications, are critical drivers of disease initiation, progression, and treatment resistance. Incorporating these insights into pathology practices is essential for accurately classifying diseases, predicting clinical outcomes, and selecting targeted therapies. For instance, in oncology, molecular profiling of tumors through NGS has enabled the identification of actionable mutations, guiding the prescription of targeted therapies such as tyrosine kinase inhibitors (TKIs).6

Data Deluge: Challenges and Opportunities

The integration of genomic data into pathology workflows poses significant challenges. Handling and interpreting large-scale genomics data necessitate advanced bioinformatics expertise and infrastructure. Moreover, ensuring data privacy and security, while enabling data sharing for research and clinical purposes, requires innovative solutions. Collaborative efforts, such as data sharing consortia, have emerged to address these challenges. To achieve the goals of precision medicine, certified standards for measurement devices like in vitro diagnostics (IVDs), radiology equipment, and others will be essential. For instance, consider the PD-(L)1 expression assay, which demands a wealth of information beyond a mere positive or high-expression result. This assay encompasses various tests utilizing distinct reagents and measurement thresholds, all of which contribute crucial data for a diagnostic algorithm. To ensure viability and foster widespread acceptance, it may be imperative to first establish and validate a minimal set of fundamental variables before embarking on broader data collection endeavors.

To harness the power of this data, pathology departments need to adopt sophisticated data management systems that can aggregate, analyze, and interpret diverse datasets. Integrating histopathological, genomic, proteomic, and clinical data will create a comprehensive view of disease mechanisms, paving the way for more accurate diagnoses and targeted treatments.7

From One Dimension Diagnosis to Multi-omics Integration

Traditionally, pathology focused on single biomarkers or histopathological features for diagnosis and prognosis. Precision medicine, however, demands a comprehensive view of the patient's molecular landscape. Integrating multi-omics data, such as genomics, transcriptomics, proteomics, and metabolomics, allows for a more holistic understanding of disease heterogeneity and treatment responses.7,8,9 This requires pathologists to collaborate closely with bioinformaticians and biostatisticians to decipher complex data patterns and extract clinically relevant insights.

Advanced Imaging and Diagnostics

The advent of cutting-edge imaging technologies has redefined how pathologists visualize and analyze tissues. Digital pathology, for instance, enables the digitization of glass slides, allowing for remote access, archiving, and sharing of high-resolution images. Artificial intelligence (AI) algorithms can be trained to identify subtle patterns and anomalies in these images, aiding pathologists in making accurate diagnoses. Additionally, molecular imaging techniques, such as mass spectrometry imaging, provide spatial information about molecules within tissues, offering insights into disease heterogeneity and facilitating targeted therapies.

Beyond Boundaries: Inter-disciplinary Collaborations

Embracing precision medicine requires pathologists to engage in interdisciplinary collaborations with clinicians, geneticists, oncologists, radiologists, bioinformaticians, computational biologists, and data scientists. Cross-disciplinary communication is essential to bridge the gap between laboratory findings and clinical decision-making. In the era of telemedicine, virtual tumor boards and molecular tumor boards facilitate these collaborations, enabling experts from diverse fields to collectively analyze patient cases and devise personalized treatment strategies. By fostering collaboration, pathology can bridge gaps in knowledge and ensure a holistic approach to patient care.

Individualized Therapies and Approvals

Lately, a company has collaborated with prominent cancer centers throughout the United States, including Vanderbilt-Ingram Cancer Center and ASCO. The platform offers a proprietary solution for processing unstructured data like clinical notes and pathology images, as well as structured data such as next-generation sequencing, with the aim of providing actionable, personalized insights.

In 2017 and 2018, we witnessed the approval of two genuinely personalized therapies, Yescarta and Kymriah, specifically for leukemia and lymphoma.11 CAR-T therapies represent a form of immunotherapy in which a patient's immune cells are genetically engineered to combat cancer cells. Simultaneously, various gene therapy approaches, with CRISPR standing out prominently, are actively advancing, and we anticipate the approval of an increasing number of personalized therapies over the next 5-10 years.12

The Promise of Comprehensive Diagnostics

Rather than following the conventional approach of conducting separate and systematic trials involving relatively small groups, these breakthroughs offer a fresh perspective. This involves an innovative model where ongoing learning is fueled by abundant data and immediate analysis.

Subsequent diagnostic procedures employ cutting-edge, non-invasive technology and "omics" techniques to thoroughly evaluate various aspects of an individual's health status. During the course of treatment, patients undergo continuous monitoring, and the data generated from their outcomes are employed to fine-tune treatment plans and inform treatment algorithms for future patients. This information is provided to researchers and pharmaceutical innovators via data arrangements, allowing them to significantly enhance the process of drug development. This facilitates swift exploration of molecules and targets, identifies novel uses for existing medications, explores new combinations, and identifies specific patient groups that respond well. 13

Thorough and interconnected medical assessments are becoming progressively more vital in guaranteeing that patients get appropriate medical intervention when they need it. The most efficient diagnostic methods will depend on extensive collections of data to offer the highest level of predictability. Diagnostic firms will probably utilize various "omics" technologies, which become more valuable as more data is incorporated. In contrast to conventional single tests, "omics" technologies holistically evaluate numerous biomolecules, and sizeable datasets are essential to interpret the intricate results into practical understandings. 13

Furthermore, the Food and Drug Administration (FDA) has proactively facilitated the advancement of emerging assays and algorithm-based diagnostics by providing greater clarity regarding their regulatory framework.14

Educating the Next Generation Pathologist

To fully embrace the opportunities presented by precision medicine, pathology education needs to evolve. Incorporating bioinformatics, data analytics, and AI into curricula will equip future pathologists with the skills necessary to navigate the data-driven landscape.15,16 Continuous professional development should be encouraged to keep practicing pathologists up-to-date with the latest advancements, ensuring that they can confidently apply these techniques in clinical practice.

Opening the Aperture: Pathology’s Future

To fully realize the potential of precision medicine, the field of pathology must expand its aperture. This involves embracing interdisciplinary collaboration, adopting innovative technologies, and redefining diagnostic and prognostic criteria. Additionally, pathologists need to engage in ongoing education to stay abreast of the rapidly evolving landscape of precision medicine.

Conclusion

Precision medicine represents a seismic shift in healthcare, with data-driven insights reshaping how we we approach healthcare, offering personalized treatments that improve patient outcomes. Precision medicine is reshaping the landscape of healthcare, offering tailored interventions that maximize therapeutic efficacy and minimize adverse effects. Pathology, as a fundamental component of the diagnostic process, must embrace this paradigm shift by integrating genomics, adopting data-driven methodologies, and fostering interdisciplinary collaborations. By opening the aperture to encompass multi-omics approaches and working across traditional boundaries, pathology can unlock the full potential of precision medicine, ultimately benefiting patients and advancing the field of medicine as a whole.

**References:**

1. Wang RC, Wang Z. Precision Medicine: Disease Subtyping and Tailored Treatment. Cancers (Basel). 2023 Jul 28;15(15):3837.
2. [Hinkson IV, Davidsen TM, Klemm JD, Kerlavage AR, Kibbe WA, Chandramouliswaran I](https://pubmed.ncbi.nlm.nih.gov/28983483). **A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine.** Front Cell Dev Biol. 2017 Sep 21;5:83. doi: 10.3389/fcell.2017.00083
3. Reichert M, Webster K, Stanzl E, Aptekar J, Donoghoe N, Fleming E. Precision medicine: Opening the aperture. 2019 Feb:7-11
4. See <https://www.tempus.com/>.
5. Kamel HFM, Al-Amodi HSAB. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. Genomics Proteomics Bioinformatics. 2017 Aug;15(4):220-235.
6. Jin Y, Shao Y, Shi X, Lou G, Zhang Y, Wu X, Tong X, Yu X. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget. 2016 Sep 20;7(38):61755-61763.
7. Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022 Sep 1;41(1):265.
8. Gómez-Cebrián N, Domingo-Ortí I, Poveda JL, Vicent MJ, Puchades-Carrasco L, Pineda-Lucena A. Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments. Cancers (Basel). 2021 Sep 10;13(18):4544.
9. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics Data Integration, Interpretation, and Its Application. Bioinform Biol Insights. 2020 Jan 31;14.
10. EMA. First two CAR-T cell medicines recommended for approval in the European Union. <https://www.ema.europa.eu/news/first-two-car-t-cell-medicines-recommended-approval-european-union>
11. Sadelain M. CD19 CAR T Cells. Cell. 2017;171(7):1471 DOI: 10.1016/j.cell.2017.12.002.
12. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. Programmable repression and activation of bacterial gene expression using an engineered CRISPR–Cas system. Nucleic Acids Res 2013 41: 7429–7437.
13. Xu G, Reichert M, Webster K, Flemin E. A new vision for precision medicine in a data-driven world Precision medicine: Opening the aperture. 2019 Feb:13-19.
14. Bailey AM, Arcidiacono J, Benton KA, Taraporewala Z, Winitsky S. United States Food and Drug Administration Regulation of Gene and Cell Therapies. Adv Exp Med Biol. 2015;871:1-29.
15. Stenzinger A, Alber M, Allgäuer M, Jurmeister P, Bockmayr M, Budczies J, Lennerz J, Eschrich J, Kazdal D, Schirmacher P, Wagner AH, Tacke F, Capper D, Müller KR, Klauschen F. Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. Semin Cancer Biol. 2022 Sep;84:129-143.
16. Meroueh C, Chen ZE. Artificial intelligence in anatomical pathology: building a strong foundation for precision medicine. Hum Pathol. 2023 Feb;132:31-38.